Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diphtheria Toxin | 13 | 2008 | 18 | 1.610 |
Why?
|
| Education, Pharmacy | 3 | 2019 | 102 | 1.160 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 10 | 2008 | 101 | 1.130 |
Why?
|
| Recombinant Fusion Proteins | 11 | 2008 | 376 | 0.920 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2008 | 116 | 0.860 |
Why?
|
| Faculty, Pharmacy | 1 | 2019 | 13 | 0.720 |
Why?
|
| Schools, Pharmacy | 1 | 2019 | 36 | 0.710 |
Why?
|
| Dasatinib | 1 | 2017 | 17 | 0.600 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 63 | 0.590 |
Why?
|
| Fetal Diseases | 1 | 2017 | 64 | 0.580 |
Why?
|
| Pyrimidines | 1 | 2017 | 178 | 0.540 |
Why?
|
| Immunoglobulin G | 3 | 2008 | 481 | 0.540 |
Why?
|
| Antineoplastic Agents | 4 | 2017 | 1070 | 0.530 |
Why?
|
| Immunotoxins | 4 | 2006 | 23 | 0.450 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2010 | 77 | 0.430 |
Why?
|
| Program Development | 1 | 2013 | 240 | 0.420 |
Why?
|
| Program Evaluation | 1 | 2013 | 502 | 0.390 |
Why?
|
| Deoxycytidine | 1 | 2010 | 83 | 0.360 |
Why?
|
| Liver Diseases | 1 | 2010 | 193 | 0.320 |
Why?
|
| Leukemia, Myeloid | 4 | 2004 | 39 | 0.310 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2006 | 2 | 0.290 |
Why?
|
| Urate Oxidase | 1 | 2006 | 5 | 0.290 |
Why?
|
| Plasma | 1 | 2006 | 58 | 0.280 |
Why?
|
| Students, Pharmacy | 2 | 2019 | 79 | 0.280 |
Why?
|
| Tamoxifen | 2 | 1997 | 62 | 0.270 |
Why?
|
| Cancer Vaccines | 1 | 2006 | 61 | 0.270 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2005 | 16 | 0.270 |
Why?
|
| Interleukin-3 | 4 | 2006 | 63 | 0.260 |
Why?
|
| Blood Platelets | 1 | 2006 | 284 | 0.250 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2005 | 74 | 0.240 |
Why?
|
| Humans | 26 | 2019 | 68525 | 0.190 |
Why?
|
| Pharmacies | 1 | 2019 | 18 | 0.180 |
Why?
|
| Female | 20 | 2017 | 38015 | 0.180 |
Why?
|
| Preceptorship | 1 | 2019 | 35 | 0.180 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1998 | 32 | 0.160 |
Why?
|
| Recombinant Proteins | 4 | 2006 | 742 | 0.160 |
Why?
|
| Pregnancy Trimesters | 1 | 2017 | 14 | 0.150 |
Why?
|
| Pregnancy | 2 | 2017 | 2331 | 0.140 |
Why?
|
| Cisplatin | 1 | 1997 | 192 | 0.140 |
Why?
|
| HL-60 Cells | 4 | 1999 | 50 | 0.140 |
Why?
|
| Curriculum | 1 | 2019 | 575 | 0.130 |
Why?
|
| Anti-Infective Agents | 1 | 1997 | 166 | 0.130 |
Why?
|
| Carcinoma in Situ | 1 | 1995 | 45 | 0.130 |
Why?
|
| Interleukin-2 | 2 | 2006 | 133 | 0.120 |
Why?
|
| Consumer Advocacy | 1 | 2013 | 6 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 1995 | 330 | 0.120 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1993 | 52 | 0.120 |
Why?
|
| Melanoma | 1 | 1997 | 335 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 1993 | 87 | 0.110 |
Why?
|
| Faculty | 1 | 2013 | 56 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2010 | 7264 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 626 | 0.110 |
Why?
|
| Breast Neoplasms | 2 | 2010 | 1533 | 0.110 |
Why?
|
| Quality Improvement | 2 | 2013 | 413 | 0.110 |
Why?
|
| Universities | 1 | 2013 | 191 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 1993 | 186 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 2 | 2010 | 87 | 0.100 |
Why?
|
| Filgrastim | 2 | 2005 | 22 | 0.100 |
Why?
|
| Alanine Transaminase | 2 | 2010 | 137 | 0.100 |
Why?
|
| Male | 11 | 2010 | 37281 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2003 | 332 | 0.090 |
Why?
|
| Adult | 7 | 2008 | 21375 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2010 | 94 | 0.090 |
Why?
|
| Platelet Count | 1 | 2010 | 100 | 0.090 |
Why?
|
| Bilirubin | 1 | 2010 | 51 | 0.090 |
Why?
|
| Vancomycin Resistance | 1 | 2010 | 18 | 0.090 |
Why?
|
| Neutropenia | 1 | 2010 | 72 | 0.090 |
Why?
|
| Fever | 1 | 2010 | 96 | 0.090 |
Why?
|
| Middle Aged | 7 | 2010 | 21119 | 0.080 |
Why?
|
| Ricin | 2 | 1997 | 6 | 0.080 |
Why?
|
| Bacteremia | 1 | 2010 | 155 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2008 | 4843 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 848 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 1999 | 567 | 0.070 |
Why?
|
| Gout Suppressants | 1 | 2006 | 7 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 332 | 0.070 |
Why?
|
| Uric Acid | 1 | 2006 | 37 | 0.070 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2005 | 39 | 0.070 |
Why?
|
| Fetal Monitoring | 1 | 2005 | 20 | 0.070 |
Why?
|
| Creatinine | 1 | 2006 | 243 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2004 | 111 | 0.070 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2005 | 58 | 0.070 |
Why?
|
| Cytarabine | 1 | 2005 | 44 | 0.070 |
Why?
|
| Leukemia | 1 | 2006 | 117 | 0.070 |
Why?
|
| Aged | 5 | 2008 | 14842 | 0.070 |
Why?
|
| Cesarean Section | 1 | 2005 | 101 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 157 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2005 | 95 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 507 | 0.060 |
Why?
|
| Vidarabine | 1 | 2003 | 12 | 0.060 |
Why?
|
| Stem Cells | 1 | 2005 | 248 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2005 | 160 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2003 | 44 | 0.060 |
Why?
|
| Half-Life | 2 | 2004 | 96 | 0.060 |
Why?
|
| Antibodies | 2 | 2001 | 241 | 0.060 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2002 | 7 | 0.060 |
Why?
|
| Fentanyl | 1 | 2002 | 26 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1745 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 2004 | 852 | 0.050 |
Why?
|
| Bone Marrow | 2 | 2003 | 168 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2005 | 219 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2001 | 98 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2004 | 334 | 0.050 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1998 | 17 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2006 | 7028 | 0.050 |
Why?
|
| Mice | 4 | 2005 | 8472 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 3 | 2005 | 41 | 0.050 |
Why?
|
| Animals | 7 | 2005 | 20877 | 0.050 |
Why?
|
| Child | 2 | 2008 | 6400 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 1999 | 82 | 0.040 |
Why?
|
| Mice, SCID | 1 | 1999 | 238 | 0.040 |
Why?
|
| Neoplasms | 1 | 2010 | 1660 | 0.040 |
Why?
|
| Bone Marrow Cells | 3 | 2004 | 217 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2003 | 467 | 0.040 |
Why?
|
| Kidney | 2 | 2005 | 945 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 82 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 1999 | 489 | 0.040 |
Why?
|
| Adolescent | 2 | 2008 | 8903 | 0.040 |
Why?
|
| Luminescent Proteins | 1 | 1997 | 57 | 0.040 |
Why?
|
| Drug Incompatibility | 1 | 1997 | 7 | 0.040 |
Why?
|
| Doxorubicin | 1 | 1998 | 231 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2002 | 498 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2004 | 2790 | 0.030 |
Why?
|
| Stomatitis | 1 | 1995 | 8 | 0.030 |
Why?
|
| Temperature | 1 | 1997 | 340 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1997 | 618 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 1995 | 57 | 0.030 |
Why?
|
| Prognosis | 2 | 2003 | 2093 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 1995 | 63 | 0.030 |
Why?
|
| Macaca fascicularis | 2 | 2004 | 31 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1995 | 129 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 1995 | 91 | 0.030 |
Why?
|
| Receptors, Interleukin-3 | 2 | 2004 | 3 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1995 | 131 | 0.030 |
Why?
|
| Societies, Pharmaceutical | 1 | 2013 | 22 | 0.030 |
Why?
|
| Lung Diseases | 1 | 1995 | 175 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1993 | 43 | 0.030 |
Why?
|
| Immune System | 1 | 1993 | 63 | 0.030 |
Why?
|
| Lymphocytes | 1 | 1993 | 228 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 1995 | 307 | 0.030 |
Why?
|
| Autoimmunity | 1 | 1993 | 118 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 1995 | 951 | 0.030 |
Why?
|
| Acute Disease | 2 | 2004 | 658 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1995 | 929 | 0.020 |
Why?
|
| Thymidine | 2 | 2002 | 32 | 0.020 |
Why?
|
| Apoptosis | 1 | 1997 | 1640 | 0.020 |
Why?
|
| Linezolid | 1 | 2010 | 7 | 0.020 |
Why?
|
| Oxazolidinones | 1 | 2010 | 6 | 0.020 |
Why?
|
| Daptomycin | 1 | 2010 | 11 | 0.020 |
Why?
|
| Acetamides | 1 | 2010 | 17 | 0.020 |
Why?
|
| Plasmids | 2 | 2004 | 258 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2010 | 30 | 0.020 |
Why?
|
| Enterococcus | 1 | 2010 | 29 | 0.020 |
Why?
|
| Vancomycin | 1 | 2010 | 60 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2005 | 1849 | 0.020 |
Why?
|
| Kinetics | 2 | 1998 | 1047 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2010 | 1548 | 0.020 |
Why?
|
| Time Factors | 2 | 2005 | 4655 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 1582 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2005 | 65 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 73 | 0.020 |
Why?
|
| Nitrogen | 1 | 2005 | 57 | 0.020 |
Why?
|
| Anorexia | 1 | 2004 | 7 | 0.020 |
Why?
|
| Vasculitis | 1 | 2004 | 33 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 215 | 0.020 |
Why?
|
| Cell Survival | 2 | 1997 | 901 | 0.020 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2004 | 14 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2005 | 294 | 0.020 |
Why?
|
| Haplorhini | 1 | 2004 | 44 | 0.020 |
Why?
|
| Drug Stability | 1 | 2004 | 71 | 0.020 |
Why?
|
| Necrosis | 1 | 2005 | 239 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 322 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 40 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2004 | 120 | 0.010 |
Why?
|
| Glioma | 1 | 2005 | 140 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 532 | 0.010 |
Why?
|
| Pulmonary Blastoma | 1 | 2002 | 7 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 1026 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 2002 | 56 | 0.010 |
Why?
|
| Hypocalcemia | 1 | 2002 | 13 | 0.010 |
Why?
|
| Liver Failure | 1 | 2002 | 27 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 2002 | 57 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2002 | 164 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 1015 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 1082 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 1446 | 0.010 |
Why?
|
| United States | 1 | 2013 | 7335 | 0.010 |
Why?
|
| Gene Expression | 1 | 2004 | 770 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2002 | 121 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 444 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1118 | 0.010 |
Why?
|
| Pain | 1 | 2002 | 472 | 0.010 |
Why?
|
| KB Cells | 1 | 1997 | 9 | 0.010 |
Why?
|
| Plant Lectins | 1 | 1997 | 20 | 0.010 |
Why?
|
| Fetuins | 1 | 1997 | 2 | 0.010 |
Why?
|
| Asialoglycoproteins | 1 | 1997 | 4 | 0.010 |
Why?
|
| Plants | 1 | 1997 | 26 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 1997 | 21 | 0.010 |
Why?
|
| Spodoptera | 1 | 1997 | 21 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1998 | 289 | 0.010 |
Why?
|
| Cytokines | 1 | 2002 | 866 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 1997 | 22 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1997 | 36 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1997 | 165 | 0.010 |
Why?
|
| Fluorescence | 1 | 1997 | 104 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1997 | 56 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 1997 | 75 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 1997 | 200 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1997 | 358 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 357 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1997 | 174 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1997 | 173 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1997 | 368 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 1172 | 0.010 |
Why?
|
| Cell Line | 1 | 1997 | 1752 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2323 | 0.010 |
Why?
|